Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
Condition(s):Metastatic Melanoma; Recurrent Cutaneous Melanoma; Stage IV Cutaneous Melanoma AJCC v6 and v7Last Updated:January 10, 2024Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Metastatic Melanoma; Recurrent Cutaneous Melanoma; Stage IV Cutaneous Melanoma AJCC v6 and v7Last Updated:January 10, 2024Active, not recruiting
Condition(s):Chronic Lymphocytic LeukemiaLast Updated:September 16, 2022Active, not recruiting
Condition(s):Chronic Lymphocytic Leukemia; Small Lymphocytic LymphomaLast Updated:November 30, 2017Completed
Condition(s):Mantle Cell LymphomaLast Updated:March 4, 2024Active, not recruiting
Condition(s):Mantle Cell LymphomaLast Updated:June 22, 2020Withdrawn
Condition(s):Diffuse Large B Cell Lymphoma; Primary Mediastinal (Thymic) Large B-cell Lymphoma; Transformed Indolent Lymphoma; Recurrent Disease; Refractory CancerLast Updated:April 23, 2019Unknown status
Condition(s):Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma; Module 1: Non-GCB Diffuse Large B-Cell LymphomaLast Updated:September 15, 2016Withdrawn
Condition(s):Chronic Lymphocytic LeukemiaLast Updated:November 1, 2023Recruiting
Condition(s):Recurrent Hodgkin Lymphoma; Refractory Hodgkin LymphomaLast Updated:February 16, 2024Active, not recruiting
Condition(s):Chronic Lymphocytic LeukemiaLast Updated:December 28, 2022Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.